Compare PLBY & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLBY | GANX |
|---|---|---|
| Founded | 1953 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5M | 159.2M |
| IPO Year | 2020 | 2021 |
| Metric | PLBY | GANX |
|---|---|---|
| Price | $1.93 | $2.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $3.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.9M | 592.8K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.89 | 47.95 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $116,135,000.00 | $55,180.00 |
| Revenue This Year | $4.97 | N/A |
| Revenue Next Year | $8.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $1.41 |
| 52 Week High | $2.75 | $4.34 |
| Indicator | PLBY | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 48.65 | 64.25 |
| Support Level | $1.53 | $1.56 |
| Resistance Level | $2.64 | $3.06 |
| Average True Range (ATR) | 0.26 | 0.18 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 8.84 | 82.59 |
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.